

CACNB2 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP14868c

Specification

CACNB2 Antibody (Center) Blocking Peptide - Product Information

Primary Accession Q08289

CACNB2 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 783

Other Names

Voltage-dependent L-type calcium channel subunit beta-2, CAB2, Calcium channel voltage-dependent subunit beta 2, Lambert-Eaton myasthenic syndrome antigen B, MYSB, CACNB2, CACNLB2, MYSB

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CACNB2 Antibody (Center) Blocking Peptide - Protein Information

Name CACNB2

Synonyms CACNLB2, MYSB

Function

Beta subunit of voltage-dependent calcium channels which contributes to the function of the calcium channel by increasing peak calcium current (By similarity). Plays a role in shifting voltage dependencies of activation and inactivation of the channel (By similarity). May modulate G protein inhibition (By similarity). May contribute to beta-adrenergic augmentation of Ca(2+) influx in cardiomyocytes, thereby regulating increases in heart rate and contractile force (PubMed:36424916). Involved in membrane targeting of the alpha-1 subunit CACNA1C (PubMed:17525370).

Cellular Location

Cell membrane, sarcolemma; Peripheral membrane protein; Cytoplasmic side

Tissue Location

Expressed in all tissues.



CACNB2 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

CACNB2 Antibody (Center) Blocking Peptide - Images

CACNB2 Antibody (Center) Blocking Peptide - Background

This gene encodes a subunit of a voltage-dependent calciumchannel protein which is a member of the voltage-gated calciumchannel superfamily. The gene product was originally identified as an antigen target in Lambert-Eaton myasthenic syndrome which is anautoimmune disorder. Mutations in this gene are associated withBrugada symdrome. Alternatively spliced variants have been been identified for this gene.

CACNB2 Antibody (Center) Blocking Peptide - References

Burashnikov, E., et al. Heart Rhythm (2010) In press :Shimada, M., et al. Hum. Genet. 128(4):433-441(2010)Takeuchi, F., et al. Circulation 121(21):2302-2309(2010)Hong, K.W., et al. J. Hum. Genet. 55(6):336-341(2010)Lee, M.T., et al. Mol. Psychiatry (2010) In press :